Crestone, Inc. Enrolls First Patient in Phase 2 Clinical Trial for Novel Antibiotic CRS3123 to Treat C. difficile Infections. FDA also Grants CRS3123 ‘Qualified Infectious Disease Product’ (QIDP) and ‘Fast Track’ Designations.

Learn More:

https://www.businesswire.com/news/home/20210607005013/en/Crestone-Inc.-Enrolls-First-Patient-in-Phase-2-Clinical-Trial-for-Novel-Antibiotic-CRS3123-to-Treat-C.-difficile-Infections